Working to improve your health

31 JULY 2026

AFT Chair David Flacks to retire before the next ASM

AFT Pharmaceuticals (NZX: AFT; ASX: AFP) Chair David Flacks has today announced his intention to retire from the Board of the company within the next 12 months and after a successor has been appointed.

Speaking at the company's Annual Shareholders Meeting in Auckland Mr Flacks said: "I was appointed as Chair ahead of the company's initial public offer and listing on the New Zealand and Australian stock exchanges at the end of 2015. By this time next year, I would have served as Chair of the company for more than 12 years.

"It has been an incredible journey. From revenue of $56.2 million in FY15 to revenue of $254.7 million in FY26 and forecasting $300 million for FY27, with significant growth likely to continue in the years ahead, AFT has a record of growth that few companies in New Zealand or Australia can match.

"I would like to thank Co-founders and Executive Directors Hartley and Marree Atkinson for the opportunity to Chair this unique organisation. I will remain very interested in the company's ongoing progress."

Dr Atkinson said: "On behalf of shareholders, the Board and Marree and I, I want to thank David for his contribution to the company and help during this period of significant growth, international expansion and development as a publicly listed company. His judgement and advice have been greatly valued by the Board and management team. We look forward to continuing to work with him through the transition."

Mr Flacks' address to the 2026 ASM and the Company's Presentation to shareholders is attached and is available on the company's website at: https://investors.aftpharm.com/investors/

Released for, and on behalf of, AFT Pharmaceuticals Limited by Stuart Houliston, Chief Financial Officer.

For more information:

Investors
Dr Hartley Atkinson
Managing Director
AFT Pharmaceuticals
Tel: +64 9488 0232

Media
Richard Inder
The Project
Tel: +64 21 645 643

About AFT Pharmaceuticals

AFT is a growing New Zealand based multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription, and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs[1]. Our business model is to develop and in-license products for in our markets of Australia, New Zealand, Singapore, Malaysia, Hong Kong, USA, Canada, EU ex Ireland, and UK, and to out-license our products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit our website www.aftpharm.com.